PET Scan to Monitor Prostate Cancer After Targeted Treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older at the time you join the study
- Diagnosed with prostate adenocarcinoma (the most common type of prostate cancer)
- Planning to receive focal therapy (cryotherapy, HIFU, or NanoKnife—all treatments that freeze, heat, or destroy just the cancer area)
- Willing to have MRI scans before and after treatment
- Willing to have MRI-guided biopsies (small tissue samples taken with imaging guidance) before and after treatment
- No prior treatment for prostate cancer (no radiation, focal therapy, or chemotherapy before)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
This trial uses special PET imaging to see where progressive prostate cancer is in the body—one tracer to look at general sugar use and one designed to detect testosterone-related activity. It may help doctors better map cancer spread so future treatment planning can be more targeted.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
This trial tests a new imaging drug, 18F-Florastamin, to see if it can better detect prostate cancer that has come back after treatment. You may qualify if you have signs of recurrence and are willing to have a biopsy or additional therapy.
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.